Cargando…

Rapid decline of bacterial drug-resistance in an antibiotic-free environment through phenotypic reversion

Antibiotic resistance typically induces a fitness cost that shapes the fate of antibiotic-resistant bacterial populations. However, the cost of resistance can be mitigated by compensatory mutations elsewhere in the genome, and therefore the loss of resistance may proceed too slowly to be of practica...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunai, Anett, Spohn, Réka, Farkas, Zoltán, Lázár, Viktória, Györkei, Ádám, Apjok, Gábor, Boross, Gábor, Szappanos, Balázs, Grézal, Gábor, Faragó, Anikó, Bodai, László, Papp, Balázs, Pál, Csaba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707769/
https://www.ncbi.nlm.nih.gov/pubmed/31418687
http://dx.doi.org/10.7554/eLife.47088
_version_ 1783445912841879552
author Dunai, Anett
Spohn, Réka
Farkas, Zoltán
Lázár, Viktória
Györkei, Ádám
Apjok, Gábor
Boross, Gábor
Szappanos, Balázs
Grézal, Gábor
Faragó, Anikó
Bodai, László
Papp, Balázs
Pál, Csaba
author_facet Dunai, Anett
Spohn, Réka
Farkas, Zoltán
Lázár, Viktória
Györkei, Ádám
Apjok, Gábor
Boross, Gábor
Szappanos, Balázs
Grézal, Gábor
Faragó, Anikó
Bodai, László
Papp, Balázs
Pál, Csaba
author_sort Dunai, Anett
collection PubMed
description Antibiotic resistance typically induces a fitness cost that shapes the fate of antibiotic-resistant bacterial populations. However, the cost of resistance can be mitigated by compensatory mutations elsewhere in the genome, and therefore the loss of resistance may proceed too slowly to be of practical importance. We present our study on the efficacy and phenotypic impact of compensatory evolution in Escherichia coli strains carrying multiple resistance mutations. We have demonstrated that drug-resistance frequently declines within 480 generations during exposure to an antibiotic-free environment. The extent of resistance loss was found to be generally antibiotic-specific, driven by mutations that reduce both resistance level and fitness costs of antibiotic-resistance mutations. We conclude that phenotypic reversion to the antibiotic-sensitive state can be mediated by the acquisition of additional mutations, while maintaining the original resistance mutations. Our study indicates that restricting antimicrobial usage could be a useful policy, but for certain antibiotics only.
format Online
Article
Text
id pubmed-6707769
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-67077692019-08-26 Rapid decline of bacterial drug-resistance in an antibiotic-free environment through phenotypic reversion Dunai, Anett Spohn, Réka Farkas, Zoltán Lázár, Viktória Györkei, Ádám Apjok, Gábor Boross, Gábor Szappanos, Balázs Grézal, Gábor Faragó, Anikó Bodai, László Papp, Balázs Pál, Csaba eLife Evolutionary Biology Antibiotic resistance typically induces a fitness cost that shapes the fate of antibiotic-resistant bacterial populations. However, the cost of resistance can be mitigated by compensatory mutations elsewhere in the genome, and therefore the loss of resistance may proceed too slowly to be of practical importance. We present our study on the efficacy and phenotypic impact of compensatory evolution in Escherichia coli strains carrying multiple resistance mutations. We have demonstrated that drug-resistance frequently declines within 480 generations during exposure to an antibiotic-free environment. The extent of resistance loss was found to be generally antibiotic-specific, driven by mutations that reduce both resistance level and fitness costs of antibiotic-resistance mutations. We conclude that phenotypic reversion to the antibiotic-sensitive state can be mediated by the acquisition of additional mutations, while maintaining the original resistance mutations. Our study indicates that restricting antimicrobial usage could be a useful policy, but for certain antibiotics only. eLife Sciences Publications, Ltd 2019-08-16 /pmc/articles/PMC6707769/ /pubmed/31418687 http://dx.doi.org/10.7554/eLife.47088 Text en © 2019, Dunai et al http://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Evolutionary Biology
Dunai, Anett
Spohn, Réka
Farkas, Zoltán
Lázár, Viktória
Györkei, Ádám
Apjok, Gábor
Boross, Gábor
Szappanos, Balázs
Grézal, Gábor
Faragó, Anikó
Bodai, László
Papp, Balázs
Pál, Csaba
Rapid decline of bacterial drug-resistance in an antibiotic-free environment through phenotypic reversion
title Rapid decline of bacterial drug-resistance in an antibiotic-free environment through phenotypic reversion
title_full Rapid decline of bacterial drug-resistance in an antibiotic-free environment through phenotypic reversion
title_fullStr Rapid decline of bacterial drug-resistance in an antibiotic-free environment through phenotypic reversion
title_full_unstemmed Rapid decline of bacterial drug-resistance in an antibiotic-free environment through phenotypic reversion
title_short Rapid decline of bacterial drug-resistance in an antibiotic-free environment through phenotypic reversion
title_sort rapid decline of bacterial drug-resistance in an antibiotic-free environment through phenotypic reversion
topic Evolutionary Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707769/
https://www.ncbi.nlm.nih.gov/pubmed/31418687
http://dx.doi.org/10.7554/eLife.47088
work_keys_str_mv AT dunaianett rapiddeclineofbacterialdrugresistanceinanantibioticfreeenvironmentthroughphenotypicreversion
AT spohnreka rapiddeclineofbacterialdrugresistanceinanantibioticfreeenvironmentthroughphenotypicreversion
AT farkaszoltan rapiddeclineofbacterialdrugresistanceinanantibioticfreeenvironmentthroughphenotypicreversion
AT lazarviktoria rapiddeclineofbacterialdrugresistanceinanantibioticfreeenvironmentthroughphenotypicreversion
AT gyorkeiadam rapiddeclineofbacterialdrugresistanceinanantibioticfreeenvironmentthroughphenotypicreversion
AT apjokgabor rapiddeclineofbacterialdrugresistanceinanantibioticfreeenvironmentthroughphenotypicreversion
AT borossgabor rapiddeclineofbacterialdrugresistanceinanantibioticfreeenvironmentthroughphenotypicreversion
AT szappanosbalazs rapiddeclineofbacterialdrugresistanceinanantibioticfreeenvironmentthroughphenotypicreversion
AT grezalgabor rapiddeclineofbacterialdrugresistanceinanantibioticfreeenvironmentthroughphenotypicreversion
AT faragoaniko rapiddeclineofbacterialdrugresistanceinanantibioticfreeenvironmentthroughphenotypicreversion
AT bodailaszlo rapiddeclineofbacterialdrugresistanceinanantibioticfreeenvironmentthroughphenotypicreversion
AT pappbalazs rapiddeclineofbacterialdrugresistanceinanantibioticfreeenvironmentthroughphenotypicreversion
AT palcsaba rapiddeclineofbacterialdrugresistanceinanantibioticfreeenvironmentthroughphenotypicreversion